Archives of Gynecology and Obstetrics

, Volume 278, Issue 6, pp 531–534 | Cite as

Plasma homocysteine, vitamin B12 and folate levels in hydatidiform moles and histopathological subtypes

  • M. Kuntay Kokanalı
  • Demet Öztürkkan
  • Naim Ünsal
  • Perran Möroy
  • Tayfun Güngör
  • Leyla Mollamahmutoğlu
Original Article



To investigate the association of mole hydatidiform with plasma homocysteine, vitamin B12, and folate levels.


Sixty-eight patients diagnosed with mole hydatidiform at our clinic between February and October 2007 were assessed in a case-control study. Plasma homocysteine, vitamin B12, and folate levels, taken before evacuation of patients with hydatidiform mole, were compared with the results of 100 healthy normal pregnants of first trimester; and also plasma homocysteine, vitamin B12, and folate levels were compared according to histopathological types of mole hydatidiforms. SPSS 14.0 package program was used to analyze the data. Logarithmic transformation was applied for variables. Parameters were expressed as mean ± standard deviation.


The mean of plasma homocysteine levels was higher in molar group (0.8 ± 0.13) than in normal pregnant group (0.7 ± 0.13) and the difference was statistically significant (< 0.001). The mean of plasma vitamin B12 levels was found to be similar both in normal pregnant women (2.4 ± 0.17) and in the molars (2.4 ± 0.15) (P = 0.272). The mean of plasma folate levels was lower in molar group (1.0 ± 0.15) than in normal pregnant women (1.2 ± 0.17) and the difference was statistically significant (< 0.001). The hydatidiform moles of 68 patients were divided into two groups according to histopathological examination: 36 patients were partial moles and the others were complete. The difference of plasma mean homocysteine, vitamin B12, and folate levels in these two groups was not statistically significant. There were statistically significant differences of plasma mean homocysteine and folate levels one by one in complete and in partial moles when compared with the normal pregnants. The mean of plasma folate levels were lower (1.0 ± 0.17 for partials, 1.0 ± 0.13 for completes) and the homocysteine levels were higher (0.9 ± 0.14 for partials, 0.8 ± 0.12 for completes) than the levels of normal group.


This study suggests that there may be an association between plasma folate and homocysteine levels with hydatidiform moles. Folate may play a protective role in preventing molar pregnancy. Further controlled prospective studies are needed to investigate the possible effect of homocysteine, vitamin B12, and folate in molar pregnancies.


Mole hydatidiform Homocysteine Vitamin B12 Folate 


  1. 1.
    Di Cintio E, Parazzini F, Rosa C, Chatenoud L, Benzi G (1997) The epidemiology of gestational trophoblastic disease. Gen Diagn Pathol 143:103–108PubMedGoogle Scholar
  2. 2.
    Berkowitz R, Bernstein M, Harlow B, Rice L, Lage J, Goldstein D, Cramer D (1995) Case-control study of risk factors for partial molar pregnancy. Am J Obstet Gynecol 173(3):788–794PubMedCrossRefGoogle Scholar
  3. 3.
    Berkowitz RS, Cramer DW, Bernstein MR, Cassells S, Driscoll SG, Goldstein DP (1985) Risk factors for complete molar pregnancy from a case-control study. Am J Obstet Gynecol 152(8):1016–20PubMedGoogle Scholar
  4. 4.
    Perry DJ (1999) Hyperhomocysteinemia. Baillieres Best Pract Res Clin Haematol 12:451–477PubMedCrossRefGoogle Scholar
  5. 5.
    Garner EI, Goldstein DP, Feltmate CM, Berkowitz RS (2007) Gestational trophoblastic disease. Clinical Obstet Gynecol 50(1):112–122CrossRefGoogle Scholar
  6. 6.
    Palmer JR (1994) Advances in the epidemiology of gestational trophoblastic disease. J Reprod Med 39:155–162PubMedGoogle Scholar
  7. 7.
    Garner EI, Lipson E, Bernstein MR, et al (2002) Subsequent pregnancy experience in patients with molar pregnancy and gestational trophoblastic tumor. J Reprod Med 47:380–386PubMedGoogle Scholar
  8. 8.
    Ashfield-Watt PA, Moat SJ, Doshi SN, McDowell IF (2001) Folate, homocysteine, endothelial function and cardiovascular disease. What is the link? Biomed Pharmacother 55:425–433PubMedCrossRefGoogle Scholar
  9. 9.
    Stanger O, Weger M, Renner W, Konetschny R (2001) Vascular dysfunction in hyperhomocysteinemia. Implications for atherothrombotic disease. Clin Chem Lab Med 39:725–733PubMedCrossRefGoogle Scholar
  10. 10.
    Nomura S, Okamoto T, Matsuo K, Iwase K, Nakanishi T, Suzuki H, Mirutani I, (1998) Serum and tissue vascular endothelial growth factor levels in hydatidiform mole. Life Sci 63(20):1793–1805PubMedCrossRefGoogle Scholar
  11. 11.
    Selhub J, Miller JW (1992) The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 55:131–138PubMedGoogle Scholar
  12. 12.
    Malinow MR, Bostom AG, Krauss RM (1999) Homocysteine, diet and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 99:178–182PubMedGoogle Scholar
  13. 13.
    Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH (1993) Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 270:2693–2698PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • M. Kuntay Kokanalı
    • 1
    • 2
  • Demet Öztürkkan
    • 1
  • Naim Ünsal
    • 1
  • Perran Möroy
    • 1
  • Tayfun Güngör
    • 1
  • Leyla Mollamahmutoğlu
    • 1
  1. 1.Department of OncologyDr Zekai Tahir Burak Woman’s Health Education and Research HospitalAnkaraTurkey
  2. 2.AnkaraTurkey

Personalised recommendations